295 related articles for article (PubMed ID: 28744795)
1. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A; Greupink R; Litjens C; Burger D; Russel FG
Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
[TBL] [Abstract][Full Text] [Related]
3. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model.
Casey BM; Bawdon RE
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):758-61. PubMed ID: 9757985
[TBL] [Abstract][Full Text] [Related]
4. Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.
Mandelbrot L; Duro D; Belissa E; Peytavin G
Antimicrob Agents Chemother; 2014 Sep; 58(9):5617-20. PubMed ID: 24982090
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Bastiaans DET; Geelen SPM; Visser EG; van der Flier M; Vermont CL; Colbers APH; Roukens M; Burger DM; van Rossum AMC;
Pediatr Infect Dis J; 2018 Oct; 37(10):1008-1010. PubMed ID: 29474261
[TBL] [Abstract][Full Text] [Related]
7. Integration of Placental Transfer in a Fetal-Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus.
Mian P; Allegaert K; Conings S; Annaert P; Tibboel D; Pfister M; van Calsteren K; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Jul; 59(7):911-925. PubMed ID: 32052378
[TBL] [Abstract][Full Text] [Related]
8. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.
McCormack SA; Best BM
Clin Pharmacokinet; 2014 Nov; 53(11):989-1004. PubMed ID: 25223699
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
Khoo S; Peytavin G; Burger D; Hill A; Brown K; Moecklinghoff C; La Porte C; Hadacek MB
AIDS Rev; 2017; 19(1):16-23. PubMed ID: 28182610
[TBL] [Abstract][Full Text] [Related]
11. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.
Wagner C; Zhao P; Arya V; Mullick C; Struble K; Au S
J Clin Pharmacol; 2017 Oct; 57(10):1295-1304. PubMed ID: 28569994
[TBL] [Abstract][Full Text] [Related]
13. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S; Ter Heine R; Colbers A; Capparelli E; Best BM; Cressey TR; Greupink R; Russel FGM; Moltó J; Mirochnick M; Karlsson MO; Burger DM
J Antimicrob Chemother; 2019 May; 74(5):1348-1356. PubMed ID: 30715324
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
Bukkems VE; van Hove H; Roelofsen D; Freriksen JJM; van Ewijk-Beneken Kolmer EWJ; Burger DM; van Drongelen J; Svensson EM; Greupink R; Colbers A
Clin Pharmacokinet; 2022 Aug; 61(8):1129-1141. PubMed ID: 35579825
[TBL] [Abstract][Full Text] [Related]
16. Methodological Approaches to Evaluate Fetal Drug Exposure.
Bouazza N; Foissac F; Hirt D; Urien S; Benaboud S; Lui G; Treluyer JM
Curr Pharm Des; 2019; 25(5):496-504. PubMed ID: 30892158
[TBL] [Abstract][Full Text] [Related]
17. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model.
Gavard L; Gil S; Peytavin G; Ceccaldi PF; Ferreira C; Farinotti R; Mandelbrot L
Am J Obstet Gynecol; 2006 Jul; 195(1):296-301. PubMed ID: 16678781
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.
Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
Br J Clin Pharmacol; 2008 May; 65(5):667-73. PubMed ID: 18093255
[TBL] [Abstract][Full Text] [Related]
19. Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling.
Roelofsen D; van Hove H; Bukkems V; Russel F; Eliesen G; Greupink R
Toxicol In Vitro; 2022 Dec; 85():105471. PubMed ID: 36096459
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
